122 related articles for article (PubMed ID: 10547238)
21. Detection of Lyme disease after OspA vaccine.
Schutzer SE; Luan J; Coyle PK
N Engl J Med; 1997 Sep; 337(11):794-5. PubMed ID: 9289653
[No Abstract] [Full Text] [Related]
22. Lyme disease vaccine.
Gerber MA
Pediatr Infect Dis J; 1999 Sep; 18(9):825-6. PubMed ID: 10493347
[No Abstract] [Full Text] [Related]
23. An effective vaccine against Lyme disease.
Crooy P; Lobet Y
J Biotechnol; 2000 Jan; 76(2-3):261-3. PubMed ID: 10656342
[No Abstract] [Full Text] [Related]
24. The Lyme disease vaccine: conception, development, and implementation.
Thanassi WT; Schoen RT
Ann Intern Med; 2000 Apr; 132(8):661-8. PubMed ID: 10766685
[TBL] [Abstract][Full Text] [Related]
25. Protection of dogs from Lyme disease with a vaccine containing outer surface protein (Osp) A, OspB, and the saponin adjuvant QS21.
Coughlin RT; Fish D; Mather TN; Ma J; Pavia C; Bulger P
J Infect Dis; 1995 Apr; 171(4):1049-52. PubMed ID: 7706788
[TBL] [Abstract][Full Text] [Related]
26. Importance of protective borreliacidal antibodies in Lyme disease immunity and serodiagnosis.
Callister SM; Schell RF
J Infect Dis; 1994 Aug; 170(2):499-500. PubMed ID: 8035047
[No Abstract] [Full Text] [Related]
27. Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice.
Fikrig E; Telford SR; Barthold SW; Kantor FS; Spielman A; Flavell RA
Proc Natl Acad Sci U S A; 1992 Jun; 89(12):5418-21. PubMed ID: 1608951
[TBL] [Abstract][Full Text] [Related]
28. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease.
Wallich R; Siebers A; Jahraus O; Brenner C; Stehle T; Simon MM
Infect Immun; 2001 Apr; 69(4):2130-6. PubMed ID: 11254567
[TBL] [Abstract][Full Text] [Related]
29. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA.
Eschner AK; Mugnai K
Parasit Vectors; 2015 Feb; 8():92. PubMed ID: 25890386
[TBL] [Abstract][Full Text] [Related]
30. Lyme disease vaccine cleared for marketing.
Miller JL
Am J Health Syst Pharm; 1999 Feb; 56(3):206. PubMed ID: 10030501
[No Abstract] [Full Text] [Related]
31. Prospects for a vaccine to prevent Lyme disease in humans.
Wormser GP
Clin Infect Dis; 1995 Nov; 21(5):1267-74. PubMed ID: 8589153
[TBL] [Abstract][Full Text] [Related]
32. Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2-5 years old.
Beran J; De Clercq N; Dieussaert I; Van Hoecke C
Clin Infect Dis; 2000 Dec; 31(6):1504-7. PubMed ID: 11096024
[TBL] [Abstract][Full Text] [Related]
33. Acquired resistance to Borrelia burgdorferi infection in the rabbit. Comparison between outer surface protein A vaccine- and infection-derived immunity.
Foley DM; Wang YP; Wu XY; Blanco DR; Lovett MA; Miller JN
J Clin Invest; 1997 Apr; 99(8):2030-5. PubMed ID: 9109448
[TBL] [Abstract][Full Text] [Related]
34. Arthropod- and host-specific gene expression by Borrelia burgdorferi.
de Silva AM; Fikrig E
J Clin Invest; 1997 Feb; 99(3):377-9. PubMed ID: 9022068
[No Abstract] [Full Text] [Related]
35. An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi.
Luke CJ; Carner K; Liang X; Barbour AG
J Infect Dis; 1997 Jan; 175(1):91-7. PubMed ID: 8985201
[TBL] [Abstract][Full Text] [Related]
36. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine.
Stover CK; Bansal GP; Hanson MS; Burlein JE; Palaszynski SR; Young JF; Koenig S; Young DB; Sadziene A; Barbour AG
J Exp Med; 1993 Jul; 178(1):197-209. PubMed ID: 8315378
[TBL] [Abstract][Full Text] [Related]
37. New vaccine targets Lyme disease. New hope for diminishing the 'great masquerader'.
Lewis C
FDA Consum; 1999; 33(3):12-7. PubMed ID: 10443184
[No Abstract] [Full Text] [Related]
38. Studies on OspA: a source of new paradigms in Lyme disease research.
Philipp MT
Trends Microbiol; 1998 Feb; 6(2):44-7. PubMed ID: 9507636
[No Abstract] [Full Text] [Related]
39. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A lyme disease vaccination.
Molloy PJ; Berardi VP; Persing DH; Sigal LH
Clin Infect Dis; 2000 Jul; 31(1):42-7. PubMed ID: 10913394
[TBL] [Abstract][Full Text] [Related]
40. Immunization with outer surface protein (Osp) A, but not OspC, provides cross-protection of mice challenged with North American isolates of Borrelia burgdorferi.
Probert WS; Crawford M; Cadiz RB; LeFebvre RB
J Infect Dis; 1997 Feb; 175(2):400-5. PubMed ID: 9203661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
